Effect of thrombocytosis on cardiovascular risk in rheumatoid arthritis

Cover Page

Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription Access

Abstract

BACKGROUND: Patients with rheumatoid arthritis have a high level of comorbidity, and their most common and socially significant conditions are cardiovascular diseases, which represent a major cause of mortality. Currently, there are no data on the differences in cardiovascular risk scales in patients with rheumatoid arthritis depending on the presence or absence of thrombocytosis.

AIM: To assess and compare cardiovascular risk according to conventional scales in patients with thrombocytosis and normal thrombocytes.

MATERIALS AND METHODS: The study involved 85 patients diagnosed with rheumatoid arthritis: 40 with thrombocytosis [including 25 (62,5%) women] and 45 with normal thrombocytes [including 29 (64,4%) women]. The following scales were used to assess risk of cardiovascular complications: Systematic COronary Risk Evaluation with adjustment factor 1.5 (mSCORE), Reynolds Risk Score (RRS), QRESEARCH Cardiovascular Risk Algorithm (QRISK3), Assessing Cardiovascular Risk to Scottish Intercollegiate Guidelines Network / SIGN to Assign Preventative Treatment (ASSIGN).

RESULTS: The obtained findings have demontrated that according to the mSCORE and RRS scales the patients of both groups had almost identical parameters; however, according to the ASSIGN and QRISK3 high risk of cardiovascular complications has been detected nearly twice as frequently in the patients with rheumatoid arthritis and thrombocytosis in comparison with those with normal level of thrombocytes. It is also worth noting that more frequent determination of high risk of cardiovascular complications by the QRISK3 was statistically significant.

CONCLUSIONS: The QRISK3 calculation has shown significantly higher prevalence of high-risk cardiovascular complications among the patients with platelet counts >450 ∙ 109/l compared with those with platelet levels within the reference values. Thus, the QRISK3 scale can be considered as more informative for estimating risk of cardiovascular complications in rheumatoid arthritis.

About the authors

Vadim I. Mazurov

North-Western State Medical University named after I.I. Mechnikov; Clinical Rheumatology Hospital No. 25

Email: maz.nwgmu@yandex.ru
ORCID iD: 0000-0002-0797-2051
SPIN-code: 6823-5482
Scopus Author ID: 16936315400
ResearcherId: J-9643-2014

MD, Dr. Sci. (Med.), Professor, Аcademician of the RAS, Honored Scientist of the Russian Federation

Russian Federation, Saint Petersburg; 30 Bolshaya Podyacheskaya St., Saint Petersburg, 190068

Evgenii S. Melnikov

North-Western State Medical University named after I.I. Mechnikov; Clinical Rheumatology Hospital No. 25

Author for correspondence.
Email: melnikovzhenya@mail.ru
ORCID iD: 0000-0002-8521-6542
SPIN-code: 4544-0596

аспирант кафедры терапии, ревматологии, экспертизы временной нетрудоспособности и качества медицинской помощи им. Э.Э. Эйхвальда

Russian Federation, Saint Petersburg; 30 Bolshaya Podyacheskaya St., Saint Petersburg, 190068

Kira P. Morozova

Clinical Rheumatology Hospital No. 25

Email: Kiramorozoba@mail.ru
ORCID iD: 0000-0002-4113-3104

MD, rheumatologist

Russian Federation, 30 Bolshaya Podyacheskaya St., Saint Petersburg, 190068

References

  1. Mazurov VI, Gaidukova IZ, Belyaeva IB. Klinicheskaya revmatologiya. Rukovodstvo dlya vrachei. 3rd ed. Moscow: E-noto; 2021. 696 p. (In Russ.)
  2. Pope JE, Choy EH. C-reactive protein and implications in rheumatoid arthritis and associated comorbidities. Semin Arthritis Rheum. 2021;51(1):219–229. doi: 10.1016/j.semarthrit.2020.11.005
  3. Bombardier C, Barbieri M, Parthan A, et al. The relationship between joint damage and functional disability in rheumatoid arthritis: a systematic review. Ann Rheum Dis. 2012;71(6):836–844. doi: 10.1136/annrheumdis-2011-200343
  4. Buttgereit F, Smolen JS, Coogan AN, Cajochen C. Clocking in: chronobiology in rheumatoid arthritis. Nat Rev Rheumatol. 2015;11(6):349–356. doi: 10.1038/nrrheum.2015.31
  5. Kim JW, Suh CH. Systemic manifestations and complications in patients with rheumatoid arthritis. J Clin Med. 2020;9(6):2008. doi: 10.3390/jcm9062008
  6. Dougados M, Soubrier M, Antunez A, et al. Prevalence of comorbidities in rheumatoid arthritis and evaluation of their monitoring: results of an international, cross-sectional study (COMORA). Ann Rheum Dis. 2014;73(1):62–68. doi: 10.1136/annrheumdis-2013-204223
  7. Kannayiram SS, Guraya A, Muojieje CC, et al. An analysis of rheumatoid arthritis hospitalizations. Cureus. 2020;12(12):e12344. doi: 10.7759/cureus.12344
  8. van Onna M, Boonen A. The challenging interplay between rheumatoid arthritis, ageing and comorbidities. BMC Musculoskelet Disord. 2016;17:184. doi: 10.1186/s12891-016-1038-3
  9. England BR, Thiele GM, Anderson DR, Mikuls TR. Increased cardiovascular risk in rheumatoid arthritis: mechanisms and implications. BMJ. 2018;361:k1036. doi: 10.1136/bmj.k1036
  10. Peters MJ, Symmons DP, McCarey D, et al. EULAR evidence-based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritis. Ann Rheum Dis. 2010;69(2):325–331. doi: 10.1136/ard.2009.113696
  11. Liao KP. Cardiovascular disease in patients with rheumatoid arthritis. Trends Cardiovasc Med. 2017;27(2):136–140. doi: 10.1016/j.tcm.2016.07.006
  12. Agca R, Hopman LHGA, Laan KJC, et al. Cardiovascular event risk in rheumatoid arthritis compared with type 2 diabetes: a 15-year longitudinal Study. J Rheumatol. 2020;47(3):316–324. doi: 10.3899/jrheum.180726
  13. Ogdie A, Yu Y, Haynes K, et al. Risk of major cardiovascular events in patients with psoriatic arthritis, psoriasis and rheumatoid arthritis: a population-based cohort study. Ann Rheum Dis. 2015;74(2):326–332. doi: 10.1136/annrheumdis-2014-205675
  14. Cooksey R, Brophy S, Kennedy J, et al. Cardiovascular risk factors predicting cardiac events are different in patients with rheumatoid arthritis, psoriatic arthritis, and psoriasis. Semin Arthritis Rheum. 2018;48(3):367–373. doi: 10.1016/j.semarthrit.2018.03.005
  15. Pujades-Rodriguez M, Duyx B, Thomas SL, et al. Rheumatoid arthritis and incidence of twelve initial presentations of cardiovascular disease: a population record-linkage cohort study in England. PLoS One. 2016;11(3):e0151245. doi: 10.1371/journal.pone.0151245
  16. Al-Ghamdi A, Attar SM. Extra-articular manifestations of rheumatoid arthritis: a hospital-based study. Ann Saudi Med. 2009;29(3):189–193. doi: 10.4103/0256-4947.51774
  17. Ehrenfeld M, Penchas S, Eliakim M. Thrombocytosis in rheumatoid arthritis. Recurrent arterial thromboembolism and death. Ann Rheum Dis. 1977;36(6):579–581. doi: 10.1136/ard.36.6.579
  18. Pines A, Kaplinsky N, Olchovsky D, et al. Recurrent transient ischemic attacks associated with thrombocytosis in rheumatoid arthritis. Clin Rheumatol. 1982;1(4):291–293. doi: 10.1007/BF02032089
  19. Casado Naranjo I, Martin Gonzalez R, Sancho Rieger J, et al. Transient ischaemic attacks associated with thrombocytosis in active rheumatoid arthritis. J Neurol Neurosurg Psychiatry. 1988;51(12):1599. doi: 10.1136/jnnp.51.12.1599
  20. Zhu L, Singh M, Lele S, et al. Assessing the validity of QRISK3 in predicting cardiovascular events in systemic lupus erythematosus. Lupus Sci Med. 2022;9(1):e000564. doi: 10.1136/lupus-2021-000564
  21. Hippisley-Cox J, Coupland C, Brindle P. Development and validation of QRISK3 risk prediction algorithms to estimate future risk of cardiovascular disease: prospective cohort study. BMJ. 2017;357:j2099. doi: 10.1136/bmj.j2099
  22. Dessein PH, Semb AG. Could cardiovascular disease risk stratification and management in rheumatoid arthritis be enhanced? Ann Rheum Dis. 2013;72(11):1743–1746. doi: 10.1136/annrheumdis-2013-203911
  23. Colaco K, Ocampo V, Ayala AP, et al. Predictive utility of cardiovascular risk prediction algorithms in inflammatory rheumatic diseases: a systematic review. J Rheumatol. 2020;47(6):928–938. doi: 10.3899/jrheum.190261
  24. Gerasimova EV, Popkova TV, Gerasimova DA, et al. Application of cardiovascular risk scales to identify carotid atherosclerosis in patients with rheumatoid arthritis. Terapevticheskii Arkhiv. 2021;93(5):561–567. (In Russ.) doi: 10.26442/00403660.2021.05.200787
  25. Błyszczuk P, Szekanecz Z. Pathogenesis of ischaemic and non-ischaemic heart diseases in rheumatoid arthritis. RMD Open. 2020;6(1):e001032. doi: 10.1136/rmdopen-2019-001032
  26. England BR, Thiele GM, Anderson DR, Mikuls TR. Increased cardiovascular risk in rheumatoid arthritis: mechanisms and implications. BMJ. 2018;361:k1036. doi: 10.1136/bmj.k1036
  27. Machlus KR, Thon JN, Italiano JE Jr. Interpreting the developmental dance of the megakaryocyte: a review of the cellular and molecular processes mediating platelet formation. Br J Haematol. 2014;165(2):227–236. doi: 10.1111/bjh.12758
  28. Garraud O, Cognasse F. Are platelets cells? And if yes, are they immune cells? Front Immunol. 2015;6:70. doi: 10.3389/fimmu.2015.00070
  29. Amaya-Amaya J, Montoya-Sanchez L, Rojas-Villarraga A. Cardiovascular involvement in autoimmune diseases. Biomed Res Int. 2014;2014:367359. doi: 10.1155/2014/367359
  30. Golebiewska EM, Poole AW. Platelet secretion: From haemostasis to wound healing and beyond. Blood Rev. 2015;29(3):153–162. doi: 10.1016/j.blre.2014.10.003
  31. Mazurov VI, Melnikov ЕS, Bashkinov RA. Effect of platelets on the course of rheumatoid arthritis and cardiovascular risk. Terapiya. 2021;7(10(52)):78–88. (In Russ.) doi: 10.18565/therapy.2021.10.78-88

Copyright (c) 2023 Eco-Vector

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies